Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced shipment restrictions following patient deaths before being partially reinstated.

Sarepta Therapeutics (SRPT) surpasses Q2 2025 estimates with strong ELEVIDYS sales and Roche milestone payments, driving revenue growth and investor optimism.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics.

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures rose 0.1%.

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.